Comparison of Outpatient Antimicrobial Therapy (OPAT) in a POIC vs. Traditional Home Health Care

PHILADELPHIA, PA (October 10, 2014) – Outpatient antimicrobial therapy (OPAT) in a physician office infusion center showed improved quality of care in contrast to a traditional home health care setting. A collaborative, retrospective study reviewed patient data from three Infectious Disease practices to compare outpatient antimicrobial treatment in a physician office infusion center (172 patients) vs. a traditional home health care setting (23 patients) over a 3-month time period (Oct to Dec 2013). Parameters evaluated for comparison were hospital admissions, visits to the emergency department as well as adherence to monitoring guidelines published by the Infectious Disease Society of America (IDSA). This study provides evidence that a physician office infusion center was superior to home health care with respect to 30-day hospital admission rates (7.5% vs. 17.4%, p=0.03) and visits to the emergency department (5.2% vs. 8.7%, p=0.49). Moreover, patient care at a physician office infusion center demonstrated improved adherence to laboratory monitoring (95% vs. 70%, p<0.001) as well as enhanced compliance with follow-up physician visits (95% vs. 53%, p<0.001) in comparison to patients treated at a home health care setting. Outpatient antimicrobial therapy delivered through a physician office infusion center offers closely supervised care with significantly improved adherence to existing monitoring guidelines and considerably lower 30-day hospital admissions. To learn more, click here.

This study was presented at IDWeek 2014™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2014
IDWeek 2014 is an annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA) and the Pediatric Infectious Diseases Society (PIDS). With the theme “Advancing Science, Improving Care,” IDWeek features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2014 took place October 8-12 at the Philadelphia Convention Center at Philadelphia, Pennsylvania. The full name of the meeting is IDWeek 2014™. For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.